Culture of Bordetella pertussis is the method most commonly used for the diagnosis of whooping cough. Although highly specific, the sensitivity of culture has repeatedly been shown to be low (5, 7). The slow growth of the bacteria is another disadvantage, requiring 3 to 5 days of incubation for isolation from clinical specimens.
Culture of Bordetella pertussis is the method most commonly used for the diagnosis of whooping cough. Although highly specific, the sensitivity of culture has repeatedly been shown to be low (5, 7) . The slow growth of the bacteria is another disadvantage, requiring 3 to 5 days of incubation for isolation from clinical specimens.
The sensitivity of pertussis diagnostic methods can be greatly improved by use of serologic assays as a complement to the culture method (5, 6, 9) . These assays rely on the development of a systemic antibody response, which delays the diagnosis of the disease. The rapid diagnostic tnethod of direct immunofluorescence can be used, but it has several drawbacks. The sensitivity of direct immunofluorescence is similar to that of culture under optimal conditions (1, 6, 10) . The specificity has been questioned, mainly due to poor commercial reagents and because of the subjective evaluation requiring trained microscopists for satisfactory results (1, 10) .
In a study by Goodman et al. (3) , it was suggest that detection of specific immunoglobulin A (IgA) to B. pertussis in nasopharyngeal (NPH) secretions may be a useful diagnostic method. In a more recent study encouraging results have been shown (13) with respect to this method. The use of more than one highly purified bacterial antigen in assays of B. pertussis antibody could, in theory, increase the sensitivity. Purified antigens would also diminish the risk of falsepositive results.
In previous studies NPH aspirates were used as samples. This test material has the advantage that specific IgA determination can be combined with tests for viral antigens with differential diagnostic significance. The possibility that other specimens, such as saliva, could be of diagnostic value has not been evaluated. Although it has been shown in several studies that NPH swabs yield more positive cultures for B. pertussis than the old cough plate, the presence of specific IgA to B. pertussis antigens in saliva has, to our knowledge, not been investigated.
The aim of the present study was to develop and standardize an enzyme-linked immunosorbent assay (ELISA) for the rapid determination of specific IgA to the filamentous hemagglutinin (FHA) and pertussis toxin (PT). The method was evaluated in NPH secretions and saliva from patients with pertussis or viral infections and healthy adults. (2) . Four liters of sterile-filtered culture supernatant, adjusted to pH 8.7, was passed through a column containing 100 ml of hydroxyapatite (HA-Ultrogel; LKB, Bromma, Sweden) equilibrated with 0.01 M sodium phosphate (pH 8.0) at a rate of 500 ml/h. After the column was washed with 500 ml of 0.01 M sodium phosphate (pH 8.0)-500 ml of 0.1 M sodium phosphate (pH 8.0), the bound material (FHA) was eluted with 0.1 M sodium phosphate (pH 7.0) containing 0.5 M NaCi. Fractions of 5 ml were collected. FHA eluted as a single peak, and the material was pooled (about 200 ml).
MATERIALS AND METHODS
Analysis by sodium dodecyl sulfate-gel electrophoresis showed the expected high-molecular-weight bands of FHA when the gels were stained with Commassie blue R-250 (Fig.  1A, lane 1) . The FHA preparation in Fig. 1A , lane 2, kindly provided by Biken (Osaka, Japan), was used in some preliminary experiments (data not shown).
PT was kindly provided by the Research Foundation for Microbiological Diseases (Biken, Osaka University, Osaka, Japan). Sodium dodecyl sulfate-gel electrophoresis of the preparation is shown in Fig. 1B , lane 2, in which no bands but the five subunits of PT can be seen. For reference, a preparation from NBL was included (Fig. 1B, lane 1) .
For determination of mucosal antibodies, a second coating layer of human serum albumin (HSA) was applied. A highly purified routine HSA preparation from NBL was used.
The enzyme conjugates used for serum antibody determinations were swine anti-human IgG, IgM, and IgA (lots MC1, LM3, and MC2, respectively; Orion Diagnostica, Espoo, Finland). Dilutions of 1:100, 1:50, and 1:25, respectively, were chosen by checkerboard titrations against negative and positive sera. For the mucosal IgG determination, anti-human IgG (Orion) was used at a 1:50 dilution. Other anti-human IgA conjugates investigated for the mucosal IgA determination were rabbit anti-human IgA (lot 0.75; DAKOpatts, Copenhagen, Denmark), goat anti-human IgA (lot E218; ICN Immuno Biologicals, Lisle, 111.), and goat antihuman IgA (lot 36 F8990; Sigma Chemical Co., St. Louis, Mo.).
ELISA for specific IgA and IgG determinations in mucosal secretions. Coating of cobalt-irradiated 96-well polystyrene microplates (M129B; Dynatech, Plochingen, Federal Republic of Germany) with FHA (2 ,ug/ml) and PT (1 ,ug/ml) diluted in PBS (pH 7.2) was done at room temperature (22°C) overnight. Volumes of 100 pul were used throughout the test. The plates were washed with physiological saline supplemented with 0.05% Tween 20 four times between each step. The second coating layer of 2% HSA in PBS was added, and the plates were incubated for 1 h at 22°C. The plates thus coated were either usèd immediately or could be kept at -70°C for at least 2 months. The NPH aspirates and saliva samples were screened at a final dilution of 1:100 ( higher were retested in threefold dilution steps. Samples with A405 values of 0.2 or lower were retested at a final dilution of 1:20. The samples were incubated with antigens for 1 h at 22°C. All determinations were made in duplicate and were repeated if the variation coefficient was 10% or more. Incubation with the rabbit anti-human IgA (DAKOpatts) used throughout this study at a dilution of 1:150 was done for 1 h at 22°C. After the addition of the substrate p-nitrophenyl phosphate (Sigma), the A405 values were determined when the positive and negative controls had reached certain predetermined values, i.e., after 20 to 30 min.
The ELISA for IgG determination was performed under the same conditions as the IgA assay by using a final 1:20 dilution of the specimens. The IgG conjugate (Orion) was used at a dilution of 1:50.
In Fig. 2 through 5, IgA titers are expressed in relation to the upper limit of normal values for age (cutoff level). The cutoff level established in healthy controls was set at 1, and the samples were adjusted accordingly.
ELISA for antibody determination in serum. The ELISA for antibody determination in serum was performed essentially as described previously (5) . PT was used at a coating dose of 1 ktg/ml, and FHA was used at 2 ,ug/ml. Serum samples were tested in duplicate by single-point determination at a dilution of 1:500. Higher dilutions were made, if necessary, to demonstrate increases in titer. Coating was done overnight at room temperature (22°C), and the plates were kept frozen at -70°C until use. Serum incubation was for 1 h at 22°C for IgG and IgA determinations and 2 h at 37°C for IgM. Incubation with the alkaline phosphate conjugates to human IgG, IgM, and IgA (Orion) was done at 22°C overnight. The substrate was added at 22°C, and the reading of the microplates was done in a Titertek Multiscan apparatus (Flow Laboratories, Irvine, Scotland), when the positive controls reached predetermined values (after 45 to 65 min). A significant increase in titers was defined as at least a twofold increase between paired samples.
Neutralization test for PT. The neutralization test for PT was done as described previously (4 min was chosen but could be reduced to 30 min. The incubation time for the samples was varied from 15 to 60 min; but slight losses of sensitivity were noted with decreasing times, and therefore, 60 min of incubation was used.
A second coating layer of BSA or HSA both decreased the nonspecific background. No difference was found with the patient samples supplemented with BSA before they were frozen. Such a supplement to the samples prior to freezing was not found to be necessary in later studies. A second coating with HSA was therefore chosen to avoid introduction of another species in the detection system.
The upper limit of normal A405 values determined in the negative control samples was set at mean ± 3 standard deviations. For mucosal IgA to FHA, the cutoff levels were set at 0.07, 0.14, 0.21, and 0.3 in age groups of <3 years, 4 to 7 years, 8 to 15 years, and adults, respectively, by using 1:20 dilutions of the NPH aspirates and saliva samples. For secretory IgA to PT, the cutoff levels were 0.15, 0.48, and 0.77 in the age groups of <3 years, 4 to 15 years, and adults, respectively. One 12-month-old child with respiratory syncytial virus infection who was used as a control showed a high secretory IgA titer to PT. Scrutiny of the case history of the child disclosed that the child had a culture-confirmed B. pertussis infection 7 weeks before admission for the respiratory syncytial virus infection at the time of the sampling. This child was excluded from the calculation of the cutoff levels but was included in the data given in Fig. 2  and 3 .
Specific IgA in NPH aspirates. Specific IgA to FHA was detected in a total of 38 of 54 (70%) and to PT in 28 of 54 (52%) NPH samples taken during the time of the first visit of the patients with pertussis ( serology-confirmed cases it was 20.6 + 9 days (range, 5 to 42 days; P < 0.001). The relation of disease duration at the time of sampling to the sensitivity of the IgA assay is shown in Table 2 . During the first week of disease, 65% of the patients were positive for either antigen. This rate increased to 87% during the second week and was 89 to 92% during the following weeks. The differences were not statistically significant.
The relation between the IgA responses to FHA and PT and the time after the onset of symptoms are given in Fig. 2  and 3 . To show the kinetics of the IgA responses, Fig. 2 and 3 also include data for the second NPH samples taken at the second visit for the convalescent-phase blood samples. Adults and older children showed a much higher fold increase above cutoff levels to FHA than to PT in the first sample. IgA titers in these patients tended to decrease with time after the onset of disease, although two samples drawn as late as 90 days or more after the onset of disease were still weakly positive to FHA. In the unimmunized younger children, IgA levels showed increases over time both to PT and to FHA. Fig. 2 and 3 also illustrate the specificity of the IgA assay. All 10 patients (12 samples) with negative culture and serology had negative NPH results to both FHA and PT.
Specific IgA antibodies in saliva. The results for specific IgA antibodies in saliva in patients with pertussis are shown in Table 3 . The cutoff levels established in NPH samples were used for all age groups, as saliva samples from healthy children were not available. These cutoff levels gave negative results in 15 of 17 (88%) healthy adults and 3 of 4 (Fig. 4 and 5) . The PT in saliva from the younger children was only pronounced in late samples. In adults, a response to PT was recorded in more saliva samples (55%) than in NPH secretions (32%), but the difference was not statistically significant (Tables 1  and 3 ). Specific IgG in mucosal secretions. None of the youngest unimmunized children showed an IgG response to FHA and only 7 of 17 (41%) showed such a response to PT (Table 4) . Older children showed more of an IgG response to PT than of IgA (53 versus 27%; Tables 1 and 4 ) but less of an IgG response to FHA (33 versus 73%). Adults showed a tendency toward more of an IgG response (76%) than an IgA response (32%) to PT in NPH secretions, while the FHA response was lower. None of the differences were statistically significant.
The cutoff levels for IgG in NPH secretions to PH were established at 0.03 and 0.06 for children <3 years of age and all other groups, respectively. A common cutoff level of 0.19 was used for all age groups for IgG to FHA. With these limits, the 10 patients (12 samples) with non-pertussis disease were all negative. The IgG response in saliva from adults, with cutoff levels established in 17 healthy adult controls, was much weaker than the IgA response to both FHA and PI (Table 4) . DISCUSSION This is the first investigation of the IgA and IgG responses in human mucosal secretions to purified B. pertussis FHA (38) a The specificity of the assay with these limits is shown in Fig. 4 and 5. and PT. The results indicated that determination of specific IgA to these antigens in NPH secretions represents a rapid diagnostic method for pertussis.
The finding of differences in the IgA response pattern in NPH secretions from patients of different ages was interesting. A higher IgA response to FHA in sera from adults compared with sera from infants has also been noted before (5) . The marked difference in the IgA response to PT, with 100% positive responses in the youngest children versus some 30% in older children and adults, was unexpected. Whether the difference was due to the difference in age or in immunization status or a combination of both factors cannot be answered from the results of the present study. In Sweden, general immunization against pertussis was discontinued in 1979. All the children in the study born prior to the cessation were immunized, while all the younger children were unimmunized.
Determination of IgG antibodies was made to investigate the possibility that the differences in IgA response could be due to an antibody competition between IgA and IgG for binding sites in the ELISA. There were no indications of a substantial competition, as some of the NPH secretions with The antibody response in mucosal secretions raises interesting questions on the role of these antibodies in disease and for immunity. The very rapid IgA response to PT in NPH secretions from all the youngest children compared with the response in those from adults seems to have little influence on the course of the disease, since the youngest unimmunized children had a more severe, typical presentation of whooping cough. The lack of a demonstrable IgG response to FHA in NPH secretions from this age group in the natural disease raises another question concerning the relevance of this antigen for protection against pertussis disease, colonization, or both. Our earlier finding of a low and transient IgG response to FHA in serum pointed in the same direction (5). Antibody to FHA has been shown to protect mice against both intranasal and intracerebral challenge with B. pertussis (12) (8, 14) . The delayed clinical suspicion of pertussis, especially in immunized children and adults, favorably influences the sensitivity of the assay in such a setting.
The increase in the rate of positive results and in the height of titers with disease duration in the IgA assay shows the opposite kinetics of the sensitivity of culture for B. pertussis. The IgA assay therefore also represents a valuable complement to culture. The same decrease in sensitivity with disease duration is seen in serology, i.e., in terms of positive serology based on titer rises. Patients seeking medical care after several weeks of disease tend to have high titers already in their acute sample. The interpretation of these serologic responses based on high titers is more difficult and can be less specific than diagnosis based on titer rises. Three patients with such a serologic response were excluded from the evaluation. For all three patients results were clear-cut and positive by the IgA test. The proportion of such cases in a population also increases in a setting with long delays by both patients and doctors. It is therefore likely that the combination of culture, specific IgA determination of FHA and PT in mucosal secretions, and serum antibody determination to the same antigens can result in a higher sensitivity than that achieved by any of the assays alone.
The specificity (100%) of the IgA assay in patients with possible pertussis excluded by culture and serology was highly satisfactory. The number of patients (n = 10) studied was small, however, due to losses in the follow-up with convalescent sera. The results obtained in this pilot study will be expanded in an ongoing large clinical study that includes several other rapid diagnostic methods.
